Low-molecular-weight heparin in the treatment of recurrent IVF–ET failure and thrombophilia: A prospective randomized placebo-controlled trial
Authors:
- 1 January 2008
- journal article
- research article
- Published by Taylor & Francis in Human Fertility
- Vol. 11 (4) , 246-253
Abstract
Introduction: Recently, thrombophilia (acquired and inherited) has been implicated in recurrent IVF–ET failure. The objective of this study was to determine the effect and safety of thromboprophylaxis using low-molecular-weight heparin (LMWH) in women with recurrent in vitro fertilization (IVF)–embryo transfer (ET) failure and thrombophilia. Methods: Eighty-three women with history of three or more previous IVF failures and who had at least one thrombophilic defect were eligible for this study. Patients were randomly allocated into two groups: Group A (n = 42) received enoxaparin 40 mg/day, and group B (n = 41) received placebo (NaCl 0.9%). Both treatments started on the day of ET and continued until delivery or foetal demise was diagnosed. The primary outcomes were the implantation, pregnancy and live birth rates. Results: Patients who received LMWH for thromboprophylaxis had a significant increase in the implantation and pregnancy rates compared with the placebo group (20.9% vs. 6.1% and 31% vs. 9.6%, respectively; p < 0.001 and p < 0.05, respectively). A significant increase in the live birth rate was observed in the heparin-treated group compared with placebo (23.8% vs. 2.8%, respectively; p < 0.05). The abortion rate was significantly higher in the placebo-treated group compared to the heparin-treated group (p < 0.05). The frequency of treatment complications did not differ between the two study groups. Conclusions: LMWH is a safe and effective thromboprophylactic treatment for women with thrombophilia and recurrent IVF–ET failures. The implantation rate, pregnancy and live birth rates are significantly increased with such treatment.Keywords
This publication has 26 references indexed in Scilit:
- Effects of enoxaparin on late pregnancy complications and neonatal outcome in women with recurrent pregnancy loss and thrombophilia: results from the Live-Enox studyFertility and Sterility, 2005
- Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacyBlood, 2005
- Antiphospholipid antibodies prevent extravillous trophoblast differentiationFertility and Sterility, 2005
- Thrombophilia and pregnancy complicationsAmerican Journal of Obstetrics and Gynecology, 2004
- Prednisone and Aspirin Improve Pregnancy Rate in Patients with Reproductive Failure and Autoimmune Antibodies: A Prospective StudyAmerican Journal of Reproductive Immunology, 2000
- Increased Frequency of Genetic Thrombophilia in Women with Complications of PregnancyNew England Journal of Medicine, 1999
- Antiphospholipid Antibody Prevalence in Patients With IVF FailureAmerican Journal of Reproductive Immunology, 1996
- Heparin-Induced Thrombocytopenia in Patients Treated with Low-Molecular-Weight Heparin or Unfractionated HeparinNew England Journal of Medicine, 1995
- Interaction of Heparin With Antiphospholipid Antibodies (APA) From the Sera of Women With Recurrent Pregnancy Loss (RPL)American Journal of Reproductive Immunology, 1995
- Thrombosis prophylaxis in obstetrics and gynaecologyBJOG: An International Journal of Obstetrics & Gynaecology, 1993